Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 9—September 2024
Research

Infection Rates and Symptomatic Proportion of SARS-CoV-2 and Influenza in Pediatric Population, China, 2023

Chao Shi1, Yuhe Zhang1, Sheng Ye1, Jiyang Zhou, Fuyu Zhu, Yumeng Gao, Yan Wang, Bingbing Cong, Shuyu Deng, You Li, Bing LuComments to Author , and Xin WangComments to Author 
Author affiliations: Nanjing Medical University, Nanjing, China (C. Shi, Y. Zhang, S. Ye, F. Zhu, B. Cong, S. Deng, Y. Li, B. Lu, X. Wang); Wuxi Centre for Disease Control and Prevention, Wuxi, China (C. Shi, J. Zhou, Y. Gao, Y. Wang, B. Lu); The University of Edinburgh, Edinburgh, Scotland, UK (Y. Li, X. Wang).

Main Article

Table 2

Proportion of symptomatic SARS-CoV-2 and influenza infections, factors of symptomatic infections, and frequency of symptoms in study of infection rates, symptomatic proportion, and age-dependent risk profiles of SARS-CoV-2 and influenza in pediatric population, China, 2023*

Characteristic SARS-CoV-2
Influenza
Symptomatic episodes, n = 47 Univariate OR (95% CI) Symptomatic episodes, n = 39 Univariate OR† (95% CI)
Overall
19/47 (40.4%)
NA

13/39 (33.3%)
NA
Age group, y
4–6 4/7 (57.1%) Referent) 11/34 (32.4%) Referent)
7–15 13/24 (54.2%) 0.9 (0.1–4.9) 2/3 (66.7%) 1.8 (0.4–9.6)
16–18
2/16 (12.5%)
0.1 (0.0–0.8)

0/2 (0.0%)
NE
Received >2 doses of COVID-19 vaccine
39/47 (83.0%)
0.3 (0.1–1.6)

NA
NA
Symptom
Fever 2/19 (10.5%) NA 6/13 (46.2%) NA
Cough 13/19 (68.4%) NA 7/13 (53.8%) NA
Sore throat 3/19 (15.8%) NA 0/13 (0.0%) NA
Congested nose 7/19 (36.8%) NA 1/13 (7.7%) NA
Runny nose 9/19 (47.4%) NA 6/13 (46.2%) NA
Fatigue 1/19 (5.3%) NA 0/13 (0.0%) NA
Vomiting 1/19 (5.3%) NA 0/13 (0.0%) NA
Sneezing 0/19 (0.0%) NA 0/13 (0.0%) NA
Medical attendance 0/19 (0.0%) NA 3/13 (23.1%) NA

*NA, not applicable; NE, not estimated; OR, odds ratio (estimated using logistic regression model). †Influenza vaccination coverage was <5% and thus not included in the analysis for influenza.

Main Article

1These authors contributed equally to this article.

Page created: August 01, 2024
Page updated: August 06, 2024
Page reviewed: August 06, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external